サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1446462

脊椎生物製剤の市場規模、シェア、動向分析レポート：製品別、最終用途別、地域別、セグメント予測、2024年～2030年

Spine Biologics Market Size, Share & Trends Analysis Report By Product (Spinal Allografts, Bone Graft Substitutes, Cell-based Matrix), By End-use (Hospitals, Outpatient Facilities), By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
脊椎生物製剤の市場規模、シェア、動向分析レポート：製品別、最終用途別、地域別、セグメント予測、2024年～2030年
出版日: 2024年02月02日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

脊椎生物製剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、脊椎生物製剤の世界市場規模は、2024年から2030年にかけてCAGR 5.08％を記録し、2030年には43億8,000万米ドルに達する見込みです。

この市場を牽引しているのは、主に脊椎損傷の発生率の増加です。脊椎変形の有病率は先進国でも低開発国でも上昇傾向にあり、その結果、手術件数が増加しています。これは脊椎生物学的製剤市場に好影響を与えています。

これとは別に、脊椎固定手術における生物学的製剤の多くの利点、例えば術後時間の最小化や細胞増殖を活性化する能力などについての認識が高まっていることも、市場を後押ししています。生体材料や骨移植代替物は、脊柱変形に対する治療の選択肢として採用されつつあります。脊椎疾患を患う高齢者人口の割合が増加し、治療法としてこれらの製品の採用が増加していることから、予測期間中に脊椎生物学的製剤の市場が拡大すると予想されます。

老年人口は脊椎すべり症や椎間板変性症になりやすいです。このことは、交通事故やスポーツ外傷による外傷症例の増加と相まって、脊椎生物学的製剤の需要を促進しています。2018年に出版された低侵襲手術（MIS）のオープンアクセスジャーナルによると、低侵襲技術は幅広い脊椎病理の治療に採用されています。米国では年間約40万例が実施されており、脊椎固定術は脊椎外傷、変性疾患、腫瘍、構造異常に対して最も一般的に実施され、確立された治療法の1つであることが判明しています。

脊椎生物製剤市場のハイライト

  • 脊椎移植片分野が市場を独占し、2023年の世界売上高の58.62%を占めました。この優位性は、同種移植片の使用に伴う多くの利点に起因しています。
  • 2023年には病院セグメントが市場を独占しました。このセグメントの主な要因は、これらの施設で実施される脊椎固定術の件数が増加していることです。
  • 北米が市場を独占し、2023年のシェアは48.36%でした。同市場の成長は、安定した経済成長、低侵襲手術の採用増加、椎間板関連問題、脊柱管狭窄症、脊椎すべり症などの脊椎疾患の有病率の上昇に起因しています。
  • アジア太平洋地域は、患者数が多く、生物学的製剤の利点について患者や外科医の間で認識が高まっていることから、市場の急成長が予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 脊椎生物製剤市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助的な市場見通し。
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 脊椎生物製剤市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • 価格分析

第4章 脊椎生物製剤市場：製品推定・動向分析

  • 製品市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 製品別の世界の脊椎生物製剤市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第5章 脊椎生物製剤市場：最終用途推定・動向分析

  • 最終用途市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 最終用途別の世界の脊椎生物製剤市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第6章 脊椎生物学的製剤市場：地域推定・動向分析

  • 地域市場シェア分析、2023年および2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 市場規模と予測トレンド分析、2018年から2030年：
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Stryker
    • NuVasive, Inc.
    • Orthofix
    • DePuy Synthes（Johnson &Johnson）
    • Exactech, Inc.
    • Zimmer Biomet
    • Arthrex, Inc.
    • Medtronic
    • Organogenesis Inc.
    • Kuros Biosciences.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America spine biologics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 U.S. spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 Canada spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 8 Canada spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Europe spine biologics market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 11 Europe spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Germany spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 13 Germany spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 UK spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 15 UK spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 France spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 17 France spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 Italy spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 19 Italy spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Spain spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 21 Spain spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 Denmark spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 23 Denmark spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Sweden spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 25 Sweden spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Norway spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 27 Norway spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific spine biologics market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 China spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 32 China spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 Japan spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 34 Japan spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 India spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 36 India spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 South Korea spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 38 South Korea spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 Australia spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 40 Australia spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 Thailand spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 42 Thailand spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Latin America spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 44 Latin America spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 45 Brazil spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 46 Brazil spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Mexico spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 48 Mexico spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 49 Argentina spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 50 Argentina spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 51 MEA spine biologics market, by region, 2018 - 2030 (USD Million)
  • Table 52 MEA spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 53 MEA spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 54 South Africa spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 55 South Africa spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 58 UAE spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 59 UAE spine biologics market, by end-use, 2018 - 2030 (USD Million)
  • Table 60 Kuwait spine biologics market, by product, 2018 - 2030 (USD Million)
  • Table 61 Kuwait spine biologics market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Spine biologics market: market outlook
  • Fig. 14 Spine biologics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Spine biologics market driver impact
  • Fig. 20 Spine biologics market restraint impact
  • Fig. 21 Spine biologics market strategic initiatives analysis
  • Fig. 22 Spine biologics market: Product movement analysis
  • Fig. 23 Spine biologics market: Product outlook and key takeaways
  • Fig. 24 Spinal allografts market estimates and forecast, 2018 - 2030
  • Fig. 25 Machined bones allograft market estimates and forecast, 2018 - 2030
  • Fig. 26 Demineralized bone matrix market estimates and forecast, 2018 - 2030
  • Fig. 27 Bone graft substitutes market estimates and forecast, 2018 - 2030
  • Fig. 28 Bone morphogenetic proteins market estimates and forecast, 2018 - 2030
  • Fig. 29 Synthetic bone grafts market estimates and forecast, 2018 - 2030
  • Fig. 30 Cell-based matrix market estimates and forecast, 2018 - 2030
  • Fig. 31 Spine biologics market: end-use movement analysis
  • Fig. 32 Spine biologics market: end-use outlook and key takeaways
  • Fig. 33 Outpatient facilities market estimates and forecasts, 2018 - 2030
  • Fig. 34 Hospitals market estimates and forecasts,2018 - 2030
  • Fig. 35 Global spine biologics market: Regional movement analysis
  • Fig. 36 Global spine biologics market: Regional outlook and key takeaways
  • Fig. 37 Global spine biologics market share and leading players
  • Fig. 38 North America market share and leading players
  • Fig. 39 Europe market share and leading players
  • Fig. 40 Asia Pacific market share and leading players
  • Fig. 41 Latin America market share and leading players
  • Fig. 42 Middle East & Africa market share and leading players
  • Fig. 43 North America, by country
  • Fig. 44 North America market estimates and forecasts, 2018 - 2030
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 46 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 47 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 48 UK market estimates and forecasts, 2018 - 2030
  • Fig. 49 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 50 France market estimates and forecasts, 2018 - 2030
  • Fig. 51 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 52 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 53 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 54 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 55 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 56 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 57 China market estimates and forecasts, 2018 - 2030
  • Fig. 58 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 59 India market estimates and forecasts, 2018 - 2030
  • Fig. 60 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 61 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 62 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 63 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 64 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 65 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 66 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 67 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 68 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 69 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 70 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 71 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 72 Market share of key market players- Spine biologics market
目次
Product Code: GVR-3-68038-588-5

Spine Biologics Market Growth & Trends:

The global spine biologics market size is expected to reach USD 4.38 billion by 2030, registering a CAGR of 5.08% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing incidence of spinal injuries. Prevalence of spinal deformities has been on a rise in developed and underdeveloped countries and this has resulted in an increase in the number of surgeries being carried. This has had a positive impact on the market for spine biologics.

Apart from this, growing awareness about numerous advantages of biologics in spine fusion surgeries, such as minimal postoperative time and ability to activate cellular growth, has also propelled the market. Biomaterials and bone graft substitutes are being adopted as the choice of treatment for spinal deformities. Increasing percentage of the elderly population suffering from spinal disorders and rising adoption of these products as a treatment method is anticipated to boost the market for spine biologics over the forecast period.

The geriatric population is more prone to spondylolisthesis and degeneration of disc. This, coupled with increasing number of trauma cases due to road accidents and sports injuries, is driving demand for spine biologics. According to the Open Access Journal for Minimally Invasive Surgery (MIS) published in 2018, minimally invasive techniques are being adopted for the treatment of a wide range of spine pathologies. Approximately 400,000 cases are performed in the U.S. annually and spine fusion has turned out to be one of the most commonly performed and well-established treatment options for spine trauma, degenerative disorders, tumors, and structural abnormalities.

Spine Biologics Market Report Highlights:

  • The spinal allografts segment dominated the market and accounted for 58.62% of the global revenue in 2023. This dominance can be attributed to the numerous benefits associated with the usage of allografts.
  • The hospital segment dominated the market in 2023. The segment is primarily driven by an increased number of spine fusion surgeries performed in these facilities.
  • North America dominated the market and accounted for a 48.36% share in 2023. The growth of the market can be attributed to stable economic growth, increased adoption of minimally invasive surgeries, and rising prevalence of spine disorders such as disc-related issues, spinal stenosis, and spondylolisthesis.
  • Asia Pacific is anticipated to witness the fastest growth in the market due to the presence of a large patient pool and growing awareness among patients and surgeons about the advantages of biologics.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. End-use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Spine Biologics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing prevalence of spine deformities
      • 3.2.1.2. Rising technological advancements in spine biologics
      • 3.2.1.3. Increasing geriatric population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of bone grafts
      • 3.2.2.2. Stringent regulatory requirements for approval of biologics
  • 3.3. Spine Biologics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. Pricing Analysis

Chapter 4. Spine Biologics Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Spine Biologics Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Spinal Allografts
      • 4.4.1.1. Spinal Allografts Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Machined Bones Allograft
      • 4.4.1.2.1. Machined Bones Allograft Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Demineralized Bone Matrix
      • 4.4.1.3.1. Demineralized Bone Matrix Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Bone Graft Substitutes
      • 4.4.2.1. Bone Graft Substitutes Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Bone Morphogenetic Proteins
      • 4.4.2.2.1. Bone Morphogenetic Proteins Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Synthetic Bone Grafts
      • 4.4.2.3.1. Synthetic Bone Grafts Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Cell-based Matrix
      • 4.4.3.1. Cell-based Matrix Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Spine Biologics Market: End-use Estimates & Trend Analysis

  • 5.1. End-use Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Spine Biologics Market by End-use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hospitals
      • 5.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Outpatient Facilities
      • 5.4.2.1. Outpatient Facilities Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Spine Biologics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Stryker
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. NuVasive, Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Orthofix
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. DePuy Synthes (Johnson & Johnson)
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Exactech, Inc.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Zimmer Biomet
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Arthrex, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Medtronic
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Organogenesis Inc.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Kuros Biosciences.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives